Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00804362 · ClinicalTrials.gov registry record

Validation of the Sickle Cell Disease Pain Burden Interview

A clinical trial of Pain and Sickle Cell Disease, sponsored by Connecticut Children's Medical Center.

Completed
Registry status
131
Enrollment target
1
Study location

NCT00804362: Completed study of Pain and Sickle Cell Disease, sponsored by Connecticut Children's Medical Center.

NCT00804362 is a study of Pain and Sickle Cell Disease that has completed, run by Connecticut Children's Medical Center. The registered enrollment target is 131 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00804362, a study of Pain and Sickle Cell Disease, has completed, sponsored by Connecticut Children's Medical Center.

COMPLETED
Registry status
131 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to validate a brief survey tool, the SCD Pain Burden Interview (SCPBI), which can be used in the clinical and/or research settings to assess the impact of pain on children with sickle cell disease.

Conditions Studied

Study Locations (1)

Connecticut

  • Connecticut Children's Medical Center - Hartford

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2008-12
Est. Completion 2012-12

What the finished NCT00804362 record still lists

NCT00804362 is an observational study that tracks outcomes without assigning an intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (57% lower).

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 0 interventions.

NCT00804362 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00804362 about?

NCT00804362 is a clinical study titled "Validation of the Sickle Cell Disease Pain Burden Interview". The purpose of this study is to validate a brief survey tool, the SCD Pain Burden Interview (SCPBI), which can be used in the clinical and/or research settings to assess the impact of pain on children with sickle cell disease.

What is the current status of trial NCT00804362?

This trial is currently completed. The enrollment target is 131 participants. The study started on 2008-12. Estimated completion is 2012-12.

What conditions does trial NCT00804362 study?

This clinical trial studies the following conditions: Pain, Sickle Cell Disease.

Who is sponsoring clinical trial NCT00804362?

This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00804362 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00804362's enrollment target sits among peer trials

131 127th of 374 higher than 248 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03051464 · 131 participants · Phase 2

    No Surgery Trial / Two Dose-escalation Strategies

  • NCT04301843 · 131 participants · Phase 2

    Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  • NCT04748549 · 131 participants · NA

    Intraoperative VR for Older Patients Undergoing TKA

  • NCT05951179 · 131 participants · Phase 2

    Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00804362, the US trial registry maintained by the National Library of Medicine. NCT00804362 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.